This website contains information for healthcare professionals in Europe on PEMAZYRE®

Please select your country:

Austria Flag Austria
Denmark Flag Denmark
Finland Flag Finland
France Flag France
Germany Flag Germany
Italy Flag Italy
Norway Flag Norway
Sweden Flag Sweden
Switzerland Flag Switzerland
United Kingdom Flag United Kingdom
home.hero.diamonds

What's on this site:

DNA helix

Mechanism of action

Histogram and magnifying glass

Efficacy

Shield and tick

Safety profile

Clock and pill

Dosing and administration schedule

Targeted medicine

FGFR2 fusion
testing

PEMAZYRE eDetail

PEMAZYRE self-directed learning

Self-directed learning material is available to complete in your own time. With the learning module you can learn about the unmet needs in cholangiocarcinoma (CCA), discuss the need for molecular profiling for early patient identification and learn more about PEMAZYRE.
home.hero.diamonds
Medical book

FGFR2 fusion testing

Discover about FGFR2 fusions in patients with CCA

External link disclaimer

Intended for licensed healthcare professionals located in the Europe.

You are now leaving the Incyte PEMAZYRE® website. This link will take you to a site that is not owned or maintained by Incyte. Incyte is not responsible for the information contained on third⁠–⁠party sites. Would you like to continue?

Yes No

Report an adverse event

Terms of Use Privacy Policy Cookie Policy

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions via their national reporting system.

EU: Adverse events should be reported to Incyte immediately by phoning +800 000 27423 (or use local numbers listed on this website [https://www.incyte.com/contact-us/medical-information]) or via email at eumedinfo@incyte.com

UK: Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk. Adverse events should also be reported to Incyte immediately by phoning 0330 100 3677 (Great Britain) or 00 800 0002 7423 (United Kingdom [Northern Ireland])

EU/PEMA/P/23/0004; UK/PEMA/P/23/0039
Date of preparation: November 2023
© 2023, Incyte Biosciences International Sarl. All rights reserved.
Marketing authorisation holder: Incyte Biosciences Distribution B.V.
PEMAZYRE, the PEMAZYRE logo and the Incyte logo are registered trademarks of Incyte

If you would like to request further medical information, please visit:
https://www.incyteglobalmedicalinformation.com/

External link disclaimer

Intended for licensed healthcare professionals located in the Europe.

You are now leaving the Incyte PEMAZYRE® website. This link will take you to a site that is not owned or maintained by Incyte. Incyte is not responsible for the information contained on third⁠–⁠party sites. Would you like to continue?

Yes No

Report an adverse event